Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cel symbols : Nvsef save search
Non-small Cell Lung Cancer Drugs Market to Grow by USD 30.23 billion| Increasing Prevalence and Incidence of Non-small Cell Lung Cancer to Boost Market Growth | Technavio
Published: 2022-03-08 (Crawled : 08:00) - prnewswire.com
AZNCF | News | $136.2 -4.19% 1.7K
|
Health Technology
|
| O: -2.09%
H: 5.03%
C: 0.85%
ALPMY | News | $9.5 -1.11% 1M
|
Manufacturing
|
| O: 1.01%
H: 0.81%
C: -0.06%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
AZN | News | $70.12 2.29% 2.24% 4.8M
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
drug cel lung cancer cancer drug cancer growth
Cell Therapy Market 2022-2026 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio
Published: 2022-03-03 (Crawled : 11:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: -0.06%
ALPMY | News | $9.5 -1.11% 1M
|
Manufacturing
|
| O: -1.78%
H: 1.63%
C: 1.5%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
BCLI A | $0.548 3.01% 2.92% 360K
|
Health Technology
|
| O: -0.64%
H: 2.09%
C: -2.25%
disease cel therapy growth
Sickle Cell Disease Treatment Market size to Record 10.83% Y-O-Y Growth Rate in 2021 | Addmedica SAS and Bristol-Myers Squibb Co. are the leading companies in the market | Technavio
Published: 2022-02-08 (Crawled : 17:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
CRSP | News M | $55.7 1.18% 1.17% 1M
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: 0.0%
treatment disease cel growth
Outlook on the CAR T-cell Therapy Global Market to 2031 - by Product Type, Indications, End-user and Region
Published: 2022-01-14 (Crawled : 14:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: -5.96%
H: 0.0%
C: 0.0%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
BLUE | $0.9568 -6.2% -6.61% 4.4M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
cel therapy t-cell
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Research Report 2021: Analysis of Yescarta, Tecartus, Kymriah, Breyanzi, & Abecma
Published: 2021-12-24 (Crawled : 14:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
| Email alert
Add to watchlist
CYAD | $0.47 -12.49% 49K
|
Health Technology
| Email alert
Add to watchlist
yescarta research kymriah cel therapy t-cell
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.